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STATEMENT OF THE ISSUES AND SUMMARY OF ARGUMENT1 
 
Plaintiffs-Appellees challenge certain claims covering human genes on the 
grounds that they are unpatentable subject matter under the law/product of nature 
doctrine.  On July 29, 2011, this court held that some of those claims (those 
covering “isolated” DNA and one covering a method) were valid, and found 
several method claims invalid.  Ass’n for Molecular Pathology v. U.S. Patent and 
Trademark Office, 653 F.3d 1329, 1350 (Fed. Cir. 2011), vacated, 132 S. Ct. 1794 
(2012).  On March 26, 2012, the United States Supreme Court granted Plaintiffs’ 
petition for a writ of certiorari, vacated this court’s judgment, and remanded the 
case to this court for further proceedings in light of Mayo Collaborative Services v. 
Prometheus Laboratories, Inc., 132 S. Ct. 1289 (2012).  On April 30, 2012, this 
court ordered the parties to file supplemental briefs addressing the applicability of 
Mayo to the “isolated DNA claims and to method claim 20 of the ‘282 patent.”  
Order, April 30, 2012, Dkt. Entry (D.E.) 275. 
Mayo reemphasized and gave new vigor to three principles for determining 
whether a law/product of nature has been “transformed” into something patentable.  
First, courts must examine whether the patent claims preempt what is unpatentable 
– such as laws and products of nature – a question that was unaddressed by the 
                                                 
1 Plaintiffs have nothing to add to the jurisdictional statement, statement of the 
case, and statement of facts found in their answering brief.  Brief for the Appellees, 
Nov. 30, 2010. 
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original majority or concurring opinions.  Second, the Court made clear that what 
is patented must be based on an “inventive concept” or “add enough” to the natural 
phenomena, or as it has said in other cases, have “markedly different 
characteristics from any found in nature.”  Under Mayo and previous Supreme 
Court precedent, trivial chemical transformations cannot meet this test.  Third, the 
Court held that the role of the courts is to decide whether claims fall within the 
law/product of nature doctrine without regard to industry reliance and the Patent 
Office’s approval of patents.  A fair application of these three principles to this 
case should lead this court to issue a new opinion and judgment affirming the 
district court as to the isolated DNA claims and claim 20 of the ‘282 patent.   
ARGUMENT 
 
I. UNDER MAYO AND OTHER SUPREME COURT PRECEDENT, THE 
ISOLATED DNA CLAIMS ARE INVALID BECAUSE THEY PREEMPT 
USE OF LAWS AND PRODUCTS OF NATURE. 
 
When patents “risk disproportionately tying up the use of the underlying 
natural laws, inhibiting their use in the making of further discoveries” Mayo, 132 
S. Ct. at 1294, they should be found to be invalid under the law/product of nature 
doctrine.  Citing its previous cases, including cases examining composition claims 
such as Diamond v. Chakrabarty, 447 U.S. 303 (1980) and Funk Brothers Seed 
Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948), the Court held that the 
law/product of nature doctrine is a robust doctrine that prohibits the patenting of 
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laws of nature, natural phenomena, or abstract ideas because “they are the basic 
tools of scientific and technological work.”  Mayo, 132 S. Ct. at 1293.  
“[M]onopolization of those tools through the grant of a patent might tend to 
impede innovation rather than it would tend to promote it.”  Id.   
Although this doctrine should not be interpreted overly broadly, id., the 
entire thrust of the Court’s unanimous opinion is that this circuit defined it far too 
narrowly in its Mayo decisions.  A fundamental component of the Court’s 
examination is whether the patent “otherwise forecloses more future invention than 
the underlying discovery could reasonably justify.”  Id. at 1301.  It is clear that 
patents on “isolated” DNA that claim laws and products of nature impermissibly 
foreclose future scientific work and innovation.     
In Mayo, the Court concluded that the patents covered a law of nature – the 
relationship between certain metabolite levels and drug efficacy in a patient.  
Although the claims involved human intervention, they monopolized this 
naturally-occurring relationship and thus were invalid.          
While it takes a human action (the administration of a thiopurine drug) to 
trigger a manifestation of this relation in a particular person, the relation 
itself exists in principle apart from any human action.  The relation is a 
consequence of the ways in which thiopurine compounds are metabolized by 
the body – entirely natural processes.  And so a patent that simply describes 
that relation sets forth a natural law.   
 
Id. at 1297.  See also id. at 1294 (Supreme Court’s precedents “warn us against 
upholding patents that claim processes that too broadly preempt the use of a natural 
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law”); Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010) (“Allowing petitioners to 
patent risk hedging would pre-empt use of this approach in all fields, and would 
effectively grant a monopoly over an abstract idea.”); Funk Bros., 333 U.S. at 130 
(“The qualities of these bacteria, like the heat of the sun, electricity, or the qualities 
of metals, are part of the storehouse of knowledge of all men. . . .  He who 
discovers a hitherto unknown phenomenon of nature has no claim to a monopoly 
of it which the law recognizes”); O'Reilly v. Morse, 56 U.S. 62, 113 (1853) (the 
patentee’s claim on any machinery or process using electric current to mark 
characters at a distance “shuts the door against inventions of other persons”).  The 
central inquiry in these cases has been:  Does the patent seek to claim a 
“‘manifestation of . . . nature, free to all men and reserved exclusively to none”?  
Mayo, 132 S. Ct. at 1293 (citing Chakrabarty, 447 U.S. at 309 (quoting Funk 
Bros., 333 U.S. at 130)). 
The “isolated” DNA claims in this case patent laws of nature and products of 
nature.  The law is the correlation between the patented DNA and the BRCA 
proteins it encodes, which in turn correspond to traits such as risk for breast and 
ovarian cancers.  The product is the DNA itself.   
Both the district court and Myriad’s own expert recognized DNA as a 
blueprint for all of the proteins, cells, and organs that make up the human body.  
A216-17; A4837-38.  Unlike other chemicals, the information encoded by DNA 
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“reflects its primary biological function:  directing the synthesis of other molecules 
in the body – namely, proteins.”  A217.  This naturally-occurring relationship 
between DNA and proteins is at the heart of the patent claims, which themselves 
define the patented DNA based on its coding for a polypeptide.  See, e.g., claim 1, 
‘282 patent (“An isolated DNA coding for a BRCA1 polypeptide, said polypeptide 
having the amino acid sequence set forth in SEQ ID No.2”).  “DNA, and in 
particular the ordering of its nucleotides, therefore serves as the physical 
embodiment of laws of nature – those that define the construction of the human 
body.”  A217.  The point of these claims and the sole use of them by Myriad is to 
uncover the informational qualities, the laws of nature that they embody.    
The laws of nature covered by the patent claims – the encoding relationship 
between a DNA molecule and a protein, and the correlations between genetic 
mutations and disease – exist independently, whether the DNA is isolated or not.  
Indeed, “isolated” DNA can be reinserted into the cell and will then code for 
proteins and transmit the same traits as previously.  A6969-72.  The isolated DNA 
molecules “serve the ends nature originally provided and act quite independently 
of any effort of the patentee.”  Funk Bros., 447 U.S. at 131.  Just as administering a 
drug triggered manifestation of a person’s natural metabolism of thiopurine in 
Mayo, isolating DNA merely makes visible a person’s inherited genetic makeup. 
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There are several aspects of the specific claims in this case that establish that 
they are unduly preemptive of laws/products of nature and therefore invalid.  First, 
because humans did not invent DNA, it is not possible to invent around the claims.  
In Mayo, the Court suggested that a claim on a new drug would not raise the 
concern that invalidated Prometheus’ patents because another company could 
develop another drug treating the same condition without infringing.  Mayo, 132 S. 
Ct. at 1302-03.  In contrast, the “isolated” DNA claims are claims that do preempt 
future use of laws and products of nature because another entity cannot invent a 
DNA molecule that encodes for the same protein and embodies a person’s BRCA1 
and BRCA2 genetic information.  A2445-46.  As a consequence, no other 
laboratory in the U.S. has been able to provide clinical testing of these genes, 
whether at lower cost, to confirm results, or to ensure testing quality.    
Indeed, the parts that result from breaking down a naturally-occurring thing 
are probably never patentable, because a patent on any such building block of 
nature would preempt all of its uses.  This is particularly true with isolated DNA, 
because Myriad never precisely isolates a BRCA1 or BRCA2 molecule with 
specific ends, but instead obtains random fragments that are the building blocks of 
the genes and chromosomes.  Pls.-Appellees’ Pet. for Panel Reh’g 6-7, Aug. 25, 
2011, D.E. 263.  In contrast, recombining aspects of nature may be patentable if 
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the result is “markedly different” in structure and function and does not preempt 
use of a law or product of nature.   
Second, the disputed claims are broader than those invalidated in Mayo.  The 
claims in Mayo covered one method of manipulating the natural law and could be 
characterized as on “narrow laws that may have limited applications.” Mayo, 132 
S. Ct. at 1302.  The isolated DNA composition claims, by contrast, preclude every 
imaginable manufacture and use of the claimed subject matter.  A7016, A7060-63.  
They thus monopolize the law correlating every human’s BRCA1/2 genes to 
particular proteins and disease risk.  They reach hundreds of millions of molecules.   
For example, claim 6 of patent ‘492 reaches any isolated DNA molecule 
coding for a mutated form of the BRCA2 polypeptide, wherein the mutated form is 
associated with susceptibility to cancer.  The claim does not specify the mutations 
nor the type of cancer that might be associated with a mutated form; yet, it 
preempts others’ work into these very questions.   
Claims 5 and 6 of patent ‘282 cover any isolated DNAs “having at least 15 
nucleotides” of the BRCA1 gene.  A664.  The claims reach the entire BRCA1/2 
genes and are therefore invalid.  See Ass’n for Molecular Pathology, 653 F.3d at 
1365 (Moore, J., concurring) (“For this claim to be patent eligible, all of the 
sequences ranging from the 15 nucleotide sequence to the full gene must be 
patentable subject matter.”).  Dicta as to the patentability of short segments of 
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DNA should be avoided.  And, as explained by experts and the dissenting opinion, 
those claims preempt scientific work to an even greater extent because molecules 
sharing at least 15 nucleotides of the BRCA1 gene appear throughout the genome.  
Id. at 1378-79 (Bryson, J., concurring in part and dissenting in part); A7017-7021; 
A7215-30.  The ability to use short DNA segments as primers or probes does not 
mitigate the impediments the patents pose to innovation, because the challenged 
claims are not limited to these uses.2 
Third, these patents give rise to the same concern expressed by Mayo that 
Prometheus’ patents “threaten to inhibit the development of more refined treatment 
recommendations (like that embodied in Mayo’s test), that combine Prometheus’ 
correlations with later discovered features of metabolites, human physiology or 
individual patient characteristics.”  Mayo, 132 S. Ct. at 1302.  The “isolated” DNA 
claims inhibit the development of more refined and advanced genetic testing, such 
as testing for large genetic rearrangements that are not detected by Myriad’s 
standard “Comprehensive BRACAnalysis” but is recommended for all patients 
receiving BRCA genetic testing, simultaneous testing of the over twenty genes 
now known to be associated with hereditary risk for breast and ovarian cancer, and 
whole genome sequencing.  See, e.g., Tom Walsh et al., Spectrum of Mutations in 
BRCA1, BRCA2, Chek2, and TP53 in Families at High Risk of Breast Cancer, 295 
                                                 
2 Plaintiffs did not challenge claims limited to the use of short segments of DNA as 
probes or primers.  See, e.g., Patent ‘473, claims 4 and 5.  A358. 
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J. of the Am. Med. Ass'n 1379, 1385-86 (2006) (finding a 12% false negative rate 
for patients from high risk families); Nat'l Comprehensive Cancer Network, NCCN 
Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk 
Assessment: Breast and Ovarian, at MS-15 (2012) (recommending that patients 
advised to seek BRCA genetic testing receive large rearrangement testing); Tom 
Walsh et al., Detection of Inherited Mutations for Breast and Ovarian Cancer 
Using Genomic Capture and Massively Parallel Sequencing, 107 PNAS 12629, 
12631-32 (2010) (estimating that testing of 21 genes correlated to breast and 
ovarian cancer, including BRCA1 and BRCA2, could be done for less than $500 
per sample); Jacob O. Kitzman et al., Noninvasive Whole-Genome Sequencing of a 
Human Fetus, 4 Sci. Translational Med. 137ra76, at 1 (2012) (showing that the 
whole fetal genome can be sequenced using “cell-free” DNA, or naturally-
occurring DNA fragments, found in the mother’s plasma); Sec'y Advisory Comm. 
on Genetics, Health, and Soc'y, Gene Patents and Licensing Practices and Their 
Impact on Patient Access to Genetic Tests (2010) (hereinafter "SACGHS Report").  
See also A2649-50, A2775, A2813, A2934-36, A2978-81, A3022. 
Moreover, these claims pose a barrier to the development of targeted cancer 
therapies.  Although the scientific community identified years ago a class of drugs 
effective in patients with BRCA mutations, there is recent evidence that the patents 
in this case have impeded the availability of these new treatments.  See Susan M. 
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Domcheck et al., Challenges to the Development of New Agents for Molecularly 
Defined Patient Subsets: Lessons from BRCA1/2 - Associated Breast Cancer, 29 J. 
on Clinical Oncology 4224 (2011).    
The US Food and Drug Administration requires an approved companion 
diagnostic test that will define the population of interest before approval is 
granted for an agent directed toward that population.  There is presently no 
US Food and Drug Administration approved diagnostic test for determining 
germline BRCA status, although mutation results have been used for more 
than a decade to make major decisions about preventive surgeries. 
 
Id. at 4225.  The patents, and the inability of others to seek regulatory approval to 
provide BRCA testing (as laboratories have done in the context of other drugs that 
are prescribed based on genetic testing), stand in the way of access to effective 
treatments for patients with BRCA mutations and their doctors.  Id.  The promise 
of personalized medicine through targeted therapies has not materialized for the 
patient community most directly affected by BRCA mutations.  Id. at 4226; see 
also Brief for Canavan Foundation et al. as Amici Curiae Supporting Petitioners at 
3-4, Ass’n for Molecular Pathology v. Myriad Genetics, Inc., 132 S. Ct. 1794 
(2012) (No. 11-725) (joined by Facing Our Risk of Cancer Empowered, the only 
national nonprofit organization devoted to hereditary breast and ovarian cancer). 
Finally, the contested claims (and similar claims) have already inhibited 
research.  Over half of all labs surveyed as part of an NHGRI-funded study 
reported “deciding not to develop a new clinical [BRCA] test because of a gene 
patent or license.”  A2672.  A similar study found that 46% felt that gene patents 
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had “delayed or limited their research.”  A2672-73.  Another researcher looking 
closely at patenting genes found that it had “persistent negative effects on 
subsequent scientific research.”   Heidi L. Williams, Intellectual Property Rights 
and Innovation: Evidence from the Human Genome 27 (Nat'l Bureau of Econ. 
Research, Working Paper No. 16213, 2010).  See also A7064 (“The Myriad and 
similar patents … impeded innovation in several ways…more significant perhaps 
is the impediment to follow-up research…[and] even for basic research…”); 
SACGHS Report at 53-54.3   
The claims curtail the ability of scientists to examine human genes.  Because 
scientific work relies on using DNA after it has been isolated, and because the 
patents do not specify a single BRCA molecule or a single use of the DNA but 
instead cover all of them, the patents give exclusivity over the BRCA1 and 
BRCA2 DNA itself, and their preemptive effect mandates a finding of invalidity.   
II. THE ISOLATED DNA CLAIMS ARE NOT BASED ON AN INVENTIVE 
CONCEPT AND DO NOT ADD ENOUGH TO THE LAWS AND 
PRODUCT OF NATURE TO BECOME PATENTABLE. 
 
Mayo reiterated that this court must analyze whether the patents sufficiently 
apply or change the law or product of nature to create a patentable invention.  
Mayo asked, does the claim arise from an “‘inventive concept’ sufficient to ensure 
                                                 
3 Plaintiffs recognize that Myriad states it has not fully enforced its patent rights 
against activity it deems to be research.  The preemption question, however, must 
be decided on the authority given Myriad by the patents, not Myriad’s actions.  
That authority allows Myriad to stop research. 
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that the patent in practice amounts to significantly more than a patent upon the 
natural law itself”?  Does it “add enough” or “simply append[] conventional steps, 
specified at a high level of generality to laws of nature [or] natural phenomena”?  
Mayo, 132 S. Ct. at 1300.  Or, as the Court previously has stated, does what is 
patented have “markedly different characteristics from any found in nature”?  
Chakrabarty, 447 U.S. at 310.   In Mayo, the Court found that the claims were not 
inventive, despite transformations that occurred during the administering of a drug 
and determining metabolite levels, because nothing of significance was added to 
the law of nature – the patient’s response to a drug.  The claims simply “inform a 
relevant audience about certain laws of nature.”  132 S. Ct. at 1298.  Accordingly, 
they did not change the law of nature into something patentable. 
Likewise, although the discovery of the BRCA genes should be credited, the 
contested claims simply do not cover a patent-eligible invention.  Isolation of DNA 
was a well-known technique at the time these patents were sought, and continues 
to be a routine, conventional preparatory step for using human genes in research 
and clinical practice.  A6963; A7037.  The only addition of the “isolated” DNA 
claims to the progress of science is disclosure of the natural law itself – the fact 
that this DNA encodes for the BRCA protein and embodies the information needed 
to understand a person’s heredity and disease susceptibility.   
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 Considering “isolated” DNA not only as a law but also a product of nature 
leads to the same conclusion.  The majority in this case and, to a lesser extent the 
concurrence, relied on the fact that a fragment of DNA consists of a different 
chemical composition than a strand of full-length DNA.  Ass’n for Molecular 
Pathology, 653 F.3d at 1352 (“cleaving … a portion of a native chromosomal 
DNA imparts on that isolated DNA a distinctive chemical identity”); Id. at 1363 
(man creates isolated DNA by “chemically altering the larger polymer to cleave off 
adjacent portions”). 4  For the majority, this distinction was dispositive. 
 This misplaced emphasis on chemical change is directly analogous to the 
circuit’s analysis in Mayo.  There, the remand panel of this court upheld the patents 
in part on the basis that the determination of the metabolite levels caused a 
chemical transformation.  Prometheus v. Mayo, 628 F.3d 1347, 1356-7 (Fed. Cir. 
2010), rev’d, 132 S. Ct. 1289 (2012).  That analysis was rejected by the Supreme 
Court.  The determination of metabolite levels “could be satisfied without 
transforming the blood, should science develop a totally different system for 
determining metabolite levels that did not involve such a transformation.”  Mayo, 
                                                 
4 As plaintiffs argued in their Petition for Panel Rehearing, the question is not 
whether a fragment of DNA is chemically different from the whole DNA, but 
whether isolated DNAs, with covalent bonds broken, are found in nature or not.  
They are.  Moreover, the court’s discussion of the chemical changes represents a 
misunderstanding of the “isolation” process.  Thus, for the reasons stated in the 
earlier petition, the DNA is not patentable under the law/product of nature 
doctrine.  Pls.-Appellees’ Pet. for Panel Reh’g 1-11, Aug. 25, 2011, D.E. 263. 
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132 S. Ct. at 1303.  And importantly, the Court said “[i]n stating that the ‘machine 
or transformation’ test is an ‘important and useful clue’ to patentability, we have 
neither said nor implied that the test trumps the ‘law of nature’ exclusion.”  Id. 
 Thus, even if something is transformed by human intervention, the 
law/product of nature doctrine may render it invalid.  In this case, should science 
develop a method of cleaving a gene’s covalent bonds while the DNA remains in 
the body, can it be seriously argued that the DNA fragments so created, but 
floating in the body, would be patentable subject matter?  If not, then the routine 
steps involved in isolating the fragments from the body cannot, under Mayo, be 
sufficient to make them patentable upon removal.  In fact, such DNA fragments 
already exist naturally in the body.  Infra, pp. 14-15.  Conversely, if the claim in 
Mayo had been a composition claim covering the blood transformed by 
administration of thiopurine and/or the steps necessary “to extract the metabolites 
from a bodily sample and determine their concentration,” Prometheus, 628 F.3d at 
1357, can it be argued that Prometheus could have patented the “transformed” 
blood?  Considering that the Supreme Court in Mayo invalidated the method as not 
sufficiently transforming the blood, it seems inconceivable that the Court would 
have upheld a composition claim that blocked every use of that blood. 
Moreover, BRCA1 and BRCA2 fragments, with covalent bonds broken, 
naturally exist in the body.  For example, such DNA fragments result from the 
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naturally-occurring processes of meiotic recombination or double strand breaks.  
Fetal and maternal genomes, including BRCA1 and BRCA2 fragments, exist in the 
maternal plasma of pregnant women, and these fragments can be used to sequence 
the entire fetal genome.  See Kitzman, supra, at 9.  And BRCA1 and BRCA2 
fragments can be found in the blood of cancer patients.  Pls.-Appellees’ Pet. for 
Panel Reh’g 1-11, Aug. 25, 2011, D.E. 263. 
 The concurrence also relied, in part, on the diagnostic utility of small 
fragments of DNA.  Ass’n for Molecular Pathology, 653 F.3d at 1365.  Diagnostic 
testing is, as the Supreme Court said repeatedly in Mayo, a “well-understood, 
routine, conventional activity” that for other genes had been and is “engaged in by 
researchers in the field.”  Mayo, 132 S. Ct. at 1294.  That activity is insufficient to 
transform a product of nature into a patentable composition.  Just as the utility of 
using the “transformed” blood in Mayo for diagnosis was insufficient to make that 
process patentable, so too the utility of using “isolated” DNA for diagnosis is 
insufficient to make “isolated” DNA patentable.  See also pp. 7-8, supra. 
 The decision in Mayo is also relevant to the patentability of cDNA.  First, 
Myriad has never argued that a single one of the challenged claims is limited to 
cDNA in its briefs.  Brief for the Appellees at 13, Nov. 30, 2010; Reply Brief for 
the Appellants, Dec. 22, 2010.  Thus, the court’s earlier discussion of the patent 
eligibility of cDNA is entirely dicta and should not be repeated.  Plaintiffs do not 
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dispute that a process for creating cDNA may be patentable under Section 101; as 
a composition, however, it is not patent-eligible.  cDNA results from the biological 
machinery of the cell, wherein naturally-occurring RNA creates its complement.  
A2608, A6974-75, A7023.  The order and effect of the cDNA sequence is dictated 
by a law of nature, not by humans.  Accordingly, the composition is not 
“inventive” as defined by the Supreme Court.  It may take human action to create 
cDNAs (though in other instances, cDNAs do exist naturally in the body through 
naturally-occurring reverse transcription and are naturally reinserted into the 
genome, A6974-75, A7013-14, A7023-24).  Yet, cDNA has value because it is 
used to inform about a patient’s genetic code – just as the method challenged in 
Mayo informs doctors about a naturally-occurring reaction to a drug.  See also 
Cochrane v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 311 (1884) (holding 
that an artificial version of naturally-occurring alizarine could not be patented 
because it was not a “new composition of matter”).  cDNA is not markedly 
different in structure, function, or preemptive effect and thus not patentable subject 
matter.  
III. MAYO REJECTS THE IDEA THAT INDUSTRY RELIANCE IS A 
FACTOR IN APPLYING THE LAW/PRODUCTOF NATURE 
DOCTRINE. 
 
Myriad submitted a brief amicus curiae in the Supreme Court in Mayo.  In 
that brief, Myriad argued that an entire industry was “built on the settled 
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expectations of the incentive provided by strong patent protection,” including the 
patents at issue in Mayo.  Brief for Myriad Genetics, Inc. as Amicus Curiae 
Supporting Respondent at 12, Mayo Collaborative Servs. v. Prometheus Labs., 132 
S.Ct. 1289 (2012) (No. 10-1150).  Myriad cited its own BRACAnalysis test as “an 
excellent example” of this phenomenon.  Id. at 15.  Myriad concluded that the 
Supreme Court should “tread very carefully when asked…to upset those 
expectations.”  Id. at 16. 
Somewhat similarly, both the majority opinion and, to an even greater 
extent, the concurrence in this case emphasized the relevance of the settled 
expectations of the industry and/or the PTO.  Thus, the majority suggested that 
“[i]f the law is to be changed, and DNA inventions excluded from the broad scope 
of § 101 contrary to the settled expectation of the inventing community, the 
decision must come not from the courts, but from Congress.”  Ass’n for Molecular 
Pathology, 653 F.3d at 1355.  The concurrence relies heavily on the idea that “we 
must be particularly wary of expanding the judicial exception to patentable subject 
matter where both settled expectations and extensive property rights are involved.”  
Id. at 1367 (Moore, J., concurring). 
In Mayo, the Supreme Court addressed this proposition for patents relating 
to the same field as gene patents and unequivocally rejected it.  The Court noted 
that there are strong countervailing interests, citing amicus briefs by the medical 
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community, including one filed by two of the plaintiffs in this case.  Mayo, 132 S. 
Ct. at 1304-05.  Patent “exclusivity can impede the flow of information that might 
permit, indeed spur, invention ...”  Id. at 1305.  The claims will tie up “critical 
scientific data that must remain widely available if physicians are to provide sound 
medical care.”  Id. (quoting Brief for American College of Medical Genetics et al. 
as Amicus Curiae 7).  The Supreme Court concluded that the courts should not 
emphasize reliance by industry or deference to the PTO at the expense of the 
harms that occur with patenting basic laws/products of nature.  See id. at 1304-05.   
Plaintiffs and their amici (the same organizations quoted approvingly by the 
Supreme Court in Mayo) identified at length the harms caused by these patents.  
Brief for Appellees at 18-20, Nov. 30, 2010.  There is considerable evidence that 
the claims have impeded clinical practice and research.  See, e.g., SACGHS Report 
at 2-4.  For periods of time, Myriad was engaged in testing that was known to be 
inadequate, supplying some patients with erroneous results.  Many patients could 
not afford to receive testing.  The claims may well be preventing life-saving 
research and treatment.  See supra, at pp. 8-11. 
This court should follow the approach of the Supreme Court.5  This court 
should not consider deference to the PTO or reliance by industry.  Instead, it 
                                                 
5 Plaintiffs recognize that there are Supreme Court statements, cited by the 
concurrence in this case, that imply the opposite.  See Ass’n for Molecular 
Pathology, 653 F.3d at 1368.  Those cases did not involve determining what is 
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should apply fairly the law/product of nature doctrine without regard to those 
factors.  According to the Supreme Court, the burden on Congress, if it disagrees, 
is not to broaden the law/product of nature doctrine to prevent patentability of 
genes, but to narrow it to allow patentability of genes. 
IV. CLAIM 20 IS INDISTINGUISHABLE FROM THE CLAIMS FOUND 
INVALID IN MAYO. 
 
 This court upheld Claim 20 of the ‘282 patent with an analysis that relied 
heavily on the remand panel’s opinion in Mayo.  The court found the “growing” 
and “determining” steps of Claim 20 transformative in the same way that the 
remand panel found the “administering” and “determining” steps transformative in 
Mayo.  Ass’n for Molecular Pathology, 653 F.3d at 1357-8.  The court found that 
the Claim 20 steps were “central to the purpose” of the claim, as the remand panel 
had found the Mayo steps “central.”  Id.  The court found the claim non-
preemptive, emphasizing the narrow nature of the preemption, as the remand panel 
had done with the Mayo claim.  Id. 
The Supreme Court in Mayo addressed each of these rationales and rejected 
them.  The processes in Claim 20, like those in Mayo “set forth laws of nature” – 
namely the effect of a drug.  “A patent that simply describes that relation sets forth 
                                                                                                                                                             
unpatentable under Section 101, and Mayo’s analysis is definitive.  See also 
Chakrabarty, 447 U.S. at 306-07 (approving patent over objections by the 
Commissioner of Patents and Trademarks).  In addition, Mayo at least makes clear 
that deference is not warranted when the issue is whether a patent is invalid under 
Section 101 in the context of medical care.  Mayo, 132 S. Ct. at 1305.   
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